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MicroRNAs (miRNAs) are a subfamily of small noncoding RNAs that play a variety of roles in 
regulating gene expression in nearly all organisms. They affect different biological pathways by post-
transcriptionally regulating mRNAs. Aside from miRNAs’  role in maintaining cellular homeostasis, 
their perturbation is related to several pathologic states and diseases. Cardiovascular disorders are 
considered some of the most mortal multifactorial diseases that are caused by the deregulation of 
network of genes and effects of environmental factors. In this review, we discuss the role of miRNAs 
in cardiac homeostasis and malfunctions. We reviewed published research on association and role of 
miRNAs  in cardiac development and diseases and investigated the possible links between regulatory 
miRNAs  and different cardiac disorders. Research shows that manipulating miRNAs expression 
affects the integrity and functionality of the cardiovascular system. Moreover, deregulation of 
miRNAs, is observed in many cardiac diseases. These findings intensify the pivotal role of miRNAs in 
the development and specific pathological disorders of the cardiovascular system. In this review, we 
summarized the latest findings on the involvement of miRNAs in cardiac development, and continued 
by their role in congenital heart diseases and rheumatic heart disease, which are some of the leading 
causes of infant death and cardiovascular morbidity and mortality. Considering the significance of 
miRNAs in cardiac homeostasis and malfunctions, they are considered as promising therapeutic 
targets in cardiovascular diseases.
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Background
Each year, more than 32,000 newborns are born with 
various forms of heart malformations (1 out of every 125 
to 150). Cardiovascular diseases constitute the principal 
cause of morbidity and mortality in adults (1). A double 
pump comprising 4 chambers, the heart, is one of the 
earliest differentiating and functioning organs and the 
most vulnerable organs to birth defects (2, 3). 
The proper development of the heart is dependent 
on a sophisticated network of crosstalk between 
multiple cell lineages; cardiomyocytes, endothelial 
cells, fibroblasts, epicardial cells, neural crest cells, 
and smooth muscle cells. This coordination occurs via 
paracrine interactions, cell–ECM interactions, and cell–
cell interactions in order to facilitate survival, growth, 
proliferation, differentiation, and migration of cardiac 
tissue(4, 5). Consequently a myriad of genes that encode 
various transcription and growth factors, adhesion 
molecules, structural proteins, signal molecules, and ion 
channels regulate cardiac morphogenesis. 
Briefly, the key points of cardiac development start 
from undifferentiated mesoderm with interfering of 
bone morphogenetic proteins (BMP), wingless-related 
integration site family member (WNT), and fibroblast 
growth factors (FGF) changing to cardiac mesoderm. 
Following this NK2 Homeobox 5 (NKX2.5), GATA-
binding factor (GATA), Myocyte enhancer factor-2 
(MEF2), T-box transcription factor (TBX), Heart- and 
neural crest derivatives-expressed protein (HAND), 
pituitary homeobox-2 (PITX2), MEF2C, Spalt Like 
Transcription Factor-4 (SALL4), Serum response factor 
(SRF), zinc finger protein, FOG family member 2 (FOG2), 
Cbp/p300 interacting transactivator with Glu/Asp rich 
carboxy-terminal domain 2 (CITED2), and Zic family 
member 3 (ZIC3) transcription factors participated 
in development of  cardiac tube, looping, cardiac 
chambers, and formation of cardiac valves, great vessels, 
and their relationships (6-8). Therefore, numerous 
control mechanisms regulate and integrate the diverse 
functions and component parts of the cardiovascular 
system. Misregulation of these processes leads to 
developmental diseases and pathological phenotypes.
The collective work of several research groups has 
highlighted that the non-protein coding parts of the 
genome, formerly believed to be junk DNA, might also be 
of functional importance. Research in the last decade has 
established that microRNAs (miRNAs), an evolutionary 
highly conserved class of non-coding RNAs (ncRNAs), 
compose the main part of the human small noncoding 
RNAs in transcriptome. In addition, given their 
highly organ- and cell-particular expression patterns, 
miRNAs are postulated to participate in regulating 
protein-coding gene expression in development and 
disease. Indeed, many research groups have recently 
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unraveled the astonishingly powerful role of miRNAs in 
the development/diseases of the cardiovascular system 
(9-12). Here, we review the role of miRNAs in cardiac 
development as well as congenital and rheumatic heart 
disease (RHD) (Table 1). In developing countries, RHD 
stands as one of the prominent causes of cardiovascular 
morbidity and mortality. We reviewed the latest findings 
on the role of miRNAs in RHD. Then, we also considered 
the therapeutic roles of miRNAs in order to develop 
the novel miRNA therapeutics for management of the 
cardiovascular diseases.
Biogenesis of miRNAs
Since the year 1993, when 2 research groups 
introduced the first non-coding miRNA-namely, lin-4-
and its interaction with the complementary sequence 
existing in the untranslated region of lin-14 messenger 
RNA (mRNA) in the nematode Caenorhabditis elegans 
(13, 14) , many investigators have identified copious 
miRNAs in the human genome. Up to now, 28 645 miRNAs 
have been submitted to the miRBase database (http://
www.mirbase.org/). These tiny ncRNAs fulfill essential 
roles in regulating a broad range of physiological 
and pathological circumstances. Manufactured from 
hairpin-shaped transcripts, miRNAs are endogenous 
single-stranded ncRNAs that are 18 to 24 nucleotides 
in length. miRNAs modulate transcriptional and post-
transcriptional gene expression via interaction with 
complementary target sites in targeted genes. It has 
been estimated that the expression of more than 60% 
of protein-coding genes is modulated by miRNAs 
(15).  Consequently, in response to pathophysiological 
phenomena, these small ncRNAs act as the fine-tuners 
or micromanagers of gene expression.
The genes of miRNAs, whether a single gene or a 
cluster of genes, can be positioned in the intergenic, 
intronic, or exonic regions of protein-coding or 
noncoding genes in the genome [8] and are mainly 
transcribed by RNA polymerase II (16). They may be 
under the control of their own miRNA-specific promoters 
or under the direction of the promoters of their host 
genes (17)(Figure 1). The primary transcript could be 
several thousand nucleotides long and contain several 
miRNA precursors. miRNAs that reside in 1 primary 
transcript are known as a cluster. miRNA precursors 
form a stable stemloop structure in primary transcript 
RNAs, which are recognized by the microprocessor 
complex, Pasha (RNA-binding protein DGCR8), and the 
ribonuclease III enzyme, Drosha(18). After being cut by 
Drosha, an miRNA-producing stemloop (now known as 
a pre-miRNA) is joined by exportin 5 and leaves the cell 
nucleus in a Ran-guanosine-5’-triphosphate-dependent 
manner. The RNase III enzyme Dicer is in charge of the 
cytoplasmic processing of pre-miRNAs and produces 
18- to 22-nucleotide long mature miRNAs. Mature 
miRNAs then couple with the RNA-induced silencing 
(RISC) complex and execute their effect by base-pairing 
with the target mRNA (19, 20). The extent of the base-


















Development of heart 
miR-1 Promotion of cardiomyocyte differentiation (31, 32) 
miR133 family Inhibition of cardiomyocyte differentiation (33, 34) 
miR-17-92 Differentiation of cardiac progenitor cell 
Cardiomyocytes proliferation in embryonic and adult hearts 
Regulation of  Bmp signaling 
(40, 41, 42, 43) 
miR-208 
miR-499 
Proliferation of cardiac muscle cells 
Control the myosin heavy chain 
(45) 
miR-20a Suppression of differentiation and proliferation 
Increase apoptosis 
(40, 42) 
miR-15 family Cardiomyocyte proliferation 




Rheumatic heart disease 
miR-1183 
miR-1299 













Congenital heart diseases 









Elevated expression in  RHD (50, 51) 
miR-1 Proliferation of ventricular cardiomyocytes (33) 
miR-421 Up-regulation in  in right ventricle of infants with tetralogy of Fallot (53) 
miR-196a Atrioventricular septal defects and cardiac valve dysfunction (47) 
miR-133a-1/ miR-1-2 
miR-133a-2/miR-1-1 
Involved in formation of  ventricular myocardium and interventricular 
septum 
(54, 55) 
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pairing miRNA to the target determines the fate of 
the target. In this context, if the miRNA has perfect or 
near-perfect complementarity to the targeted mRNA, 
it directly destroys the mRNA (21). Alternatively, an 
imperfect base-pairing between miRNAs and target 
mRNAs actuates the suppression of protein translation 
without strongly affecting mRNA levels  (11) (Figure 1).
miRNAs and the development of the heart 
Tissue-specific omission of the Dicer gene, which 
encodes an RNase III endoribonuclease that is necessary 
for miRNA processing, has revealed that miRNAs are 
indispensable for cardiovascular development in mice. 
After Dicer deletion, lethal phenotypes are observed 
in myocardial and vascular lineage (10, 22, 23). 
Additionally, the deletion of Dicer in the myocardium is 
allied to a high incidence of death, cardiac hypertrophy, 
and reactivation of the cardiac gene program (24, 25). 
Therefore, a mature heart requires Dicer activity in 
order to have a normal function.
Recently, accumulative studies have ascertained 
the participation of these small RNAs in multiple 
cardiovascular processes such as embryonic stem-cell 
differentiation, cardiomyocyte identity, contractility, ion-
channel regulation, and cardiac conduction. Molecular 
regulation of cardiomyocyte differentiation contributes 
to a major period in early heart development, as well as 
adult tissue homeostasis, and the network of miRNAs 
that govern these biological steps have been well 
reviewed in it (26, 27). Accordingly, precise and complex 
connections among various cells from distinct lineages: 
cardiomyocytes; endocardial, epicardial, and vascular 
cells; fibroblasts; and cells of the conduction system 
are required to form a healthy heart (12). miRNAs have 
been recognized in the cardiac tissue at all points of 
development; moreover, not only are they enriched in 
different cardiac cell types but also they participate in 
the specification of cell identity (28-31).
miRNAs that are specially expressed or spotted 
in cardiac, smooth, and skeletal muscles are termed 
“myo-miRNAs” or “muscle miRNAs” (32). Among them, 
4 specific miRNAs-namely miR-1, miR-133, miR-208, 
and miR-499-are extremely expressed in the different 
stages of heart development. Several non-myo-miRNAs 
have also been implicated in the development and 
differentiation of the heart.
miR-1 and miR-133 families 
miR-1, the first miRNA involved in cardiac 
development, is the prominent miRNA in cardiac 
myocytes and skeletal muscles. It is highly conserved 
from fruit flies to humans. The gene-encoding miR-1 
and miR-133 family members are clustered and co-
expressed from a common bicistronic unit. Thus far, 
research has revealed 3 clusters that are spawned in 3 
different chromosomal regions in the human genome 
and fabricate miR1-1, miR-133a-1, miR-1-2, miR-133a-2, 
miR-133b, and miR-206. The miR-1-1/miR-133a-2 and 
miR-1-2/miR-133a-1 clusters are intronic and they 
are positioned at 20q13.33 and 18q11.2, respectively. 
miR-206/133b is in an intergenic region and placed 
at 6p12.2. This cluster is homologous to miR-1, but is 
expressed exclusively in skeletal muscles (33). Although 
miR-133-a1 and miR-133-a2 have the same mature 
sequences, a single nucleotide at the 3’ end of miR-133b 
differs from the 3’ end of miR-133a (28). miR-133a is 
enriched in striated muscles (34). The expression of miR-
1 and miR-133 in the heart and skeletal muscles is under 
the control of the serum response factor/myocardin and 
the myocyte enhancer factor-2/myogenic transcription 
factors, respectively (35). Furthermore, the balance 
between the differentiation and proliferation of 
cardiac precursor cells is controlled by miR-1, which 
targets the transcription factor Hand2, which is 
involved in promoting the augmentation of ventricular 
cardiomyocytes (35). In addition miR-1 targets the 
 Figure 1. Biogenesis of microRNAs (miRNAs)
RNA polymerase II produces primary transcript RNA transcripts from miRNA genes located in the exonic, intronic, or intergenic regions of 
noncoding or protein-coding genes. Within the nucleus, Drosha, in association with Pasha (RNA-binding protein DGCR8), cleaves the primary 
transcript RNAs into precursor miRNAs (pre-miRNAs). A hairpin structure of miRNA, pre-miRNA-with the length of 60 to 100 nucleotides-is 
actively exported to the cytoplasm via exportin 5. Pre-miRNAs are cleaved by Dicer, creating double-stranded miRNA duplexes in the cytoplasm. 
Subsequently, these 22 nucleotide duplexes unwind and the guide mature miRNA enters the RNA-induced silencing (RISC) complex accompanied 
by Argonaute proteins. The binding of the miRNAs to the mRNAs target leads to the inhibition of the translation and/or mRNA degradation
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histone deacetylase (HDAC) 4, handtranscription factor 
(Hand)2, connexin 43 (GJA1), and K+ channel subunit 
Kir2.1 (KCNJ2) transcripts which are important for 
cardiac development or function (36). miR-1 and miR-
133 act cooperatively to suppress the differentiation of 
embryonic stem cells into the endoderm and ectoderm 
and promote mesoderm differentiation. In the following 
cardiac lineage, miR-1 continues the promotion of 
cardiomyocyte differentiation, whereas miR-133 
impedes the process (37). 
miR-208 and miR-499 families
miR-208a, miR-208b, and miR-499 are intronic 
miRNAs that are one to one placed in the intron of 3 
muscle-specific myosin genes-namely Myh-6, Myh-7, 
and Myh-7b. 
The main determinant of the efficiency of muscle 
contraction is dependent on the myosin heavy chain 
(MHC), the major contractile protein of cardiac and 
skeletal muscle cells. The expression of 2 MHC genes-
namely α-MHC and β-MHC-which are connected in a 
head-to-tail orientation and regulated in an antithetical 
mode, provides cardiac contractility (38). 
Mounting evidence from in vitro modeling experiments 
has revealed that the expression of these miRNAs is 
concomitant with the expression of their corresponding 
host genes during development (32, 39, 40). A collection 
of transcriptional repressors and signaling molecules 
governs the MHC expression. Similarly, the activity of 
the thyroid hormone and the stress-responsiveness of 
cardiac muscle cells are regulated by these myo-miRNAs 
(39-41). While miR-208b is chiefly expressed in atrial 
cells, miR-208a is mostly expressed in ventricular cells 
of the adult human heart.
The family members of miR-208, miR-208a, and miR-
208b share identical seed sequences. miR-499, which 
shares 6 overlapping nucleotides in the seed region, is 
extremely similar to miR-208a and miR-208b. These 
close similarities in seed sequences imply that they 
probably regulate a similar array of target genes (42).  
Cardiac-related miRNAs
Recent research has shed light on the vital role of 
the miR-17-92 cluster during in vitro differentiation 
of cardiac progenitor cells into cardiomyocytes and 
the proliferation of cardiomyocytes in embryonic and 
adult hearts (43, 44). This cluster is placed in the long 
arm of human chromosome 13, and the pri-miR-17-92 
transcript is processed into distinct mature miRNAs 
comprising miR-17-5p, miR-17-3p, miR-18a, miR-19a, 
miR-19b, miR-20a, and miR-92a. Additionally, the miR-
17-92 cluster regulates bone morphogenetic protein 
(BMP) signaling, which is involved in myocardial 
differentiation from cardiac progenitors (43). 
The overexpression of one of the members of 
this family, miR-20a, suppresses differentiation and 
proliferation and simultaneously enhances apoptosis via 
regulating the Hedgehog (Hh) signaling pathway, which 
prompts cardiac differentiation in cardiac embryonic 
development (45). The ectopic expression of miR-17-
92 represses Friend of GATA-2 expression in embryonic 
cardiomyocytes (46). Friend of GATA-2, also termed 
“ZFPM2”, is a cofactor for GATA transcription factors and 
is required for heart development (47).
The miR-15 family, which has 6 highly conserved 
miRNAs—namely miR-195, miR-15a, miR-15b, miR-
16-1, miR-16-2, and miR-497—spawned on 3 different 
chromosomes, is involved in cardiomyocyte proliferation 
and induces embryonic cardiomyocyte mitotic arrest 
through targeting multiple cell-cycle regulators (48).
miR-21 is expressed in the cardiac valve endothelium 
during development and is implicated in cardiac 
valvulogenesis via down-regulating the tumor 
suppressor Pdcd4b in the course of valve development 
(49). In addition, miR-196a, which is spotted at 
gestational age 12 to 14 weeks, controls homeobox B8/
sonic hedgehog signaling and is implicated in cardiac 
septation, morphogenesis, and valve formation (50).
miRNAs in congenital heart diseases
Structural problems of the heart existing at birth 
are known as congenital heart anomalies or congenital 
heart diseases. Ventricular septal defects, tetralogy of 
Fallot, atrial septal defects, patent ductus arteriosus, 
pulmonary valve atresia, coarctation of the aorta, 
and tricuspid atresia are among the numerous types 
of congenital heart diseases (51). Congenital heart 
diseases constitute the principal cause of morbidity 
and mortality in infants with heart problems (52, 
53). Efforts toward understanding the cellular and 
molecular mechanisms of cardiac anomalies can reduce 
the prevalence of congenital heart defects.
miR-1-1 and miR-181c are implicated in the 
pathogenesis of ventricular septal defects (54). The 
expression level of miR-1-1 is decreased in patients 
with ventricular septal defects and is associated with a 
rise in the expression level of the gap junction protein 
alpha 1 (GJA1) and SOX9 proteins. Moreover, a down-
regulation in the level of the bone morphogenetic 
protein receptor type II (BMPR2) was reported to be 
correlated with an elevated expression of miR-181c in 
affected tissues compared to healthy control tissues 
(54-56). In addition, the ectopic expression of miR-1 in 
the developing heart reduces the pool of proliferating 
ventricular cardiomyocytes via regulating the Hand2 
transcription factor, which promotes ventricular 
cardiomyocyte expansion (35). 
In one study, the circulating miRNA profile of patients 
with ventricular septal defects revealed that 7 miRNAs-
namely let-7e-5p, miR-155-5p, miR-222-3p, miR-433, 
miR-379-5p, miR-409-3p, and miR-487b-were down-
regulated and miR-498 was up-regulated in comparison 
to the normal control group (57). These miRNAs could 
be underlying the congenital abnormalities and VSD 
since they target NOTCH1, HAND1, GATA3 and ZFM2 
factors (58).  
In 2012, O’Brien et al. reported 61 miRNAs with 
significant alterations in expression levels in the 
myocardium of children with tetralogy of Fallot, in 
comparison with normally developing comparison 
subjects (59). The perturbation of miR-421 expression 
has a negative impact on SOX4, a key regulator of the 
Notch and Wnt signaling pathways, which is implicated 
in cardiac development and contributes to congenital 
defects. In an investigation, excessive expressions of miR-
421 were observed in the right ventricles of infants with 
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tetralogy of Fallot (60). The dysregulation of miR-196a 
could play a role in the formation of atrioventricular 
septal defects and cardiac valve dysfunction via 
regulating the HOXB8-Shh signaling (50). Although 
the expression of miR-133a-1/miR-1-2 and miR-
133a-2/miR-1-1 genes is detectable throughout the 
ventricular myocardium and interventricular septum 
from E8.5 until adulthood, the deletion of miR-133a-1 
or miR-133a-2 does not have obvious effects on cardiac 
development. However, the absence of both miRNAs 
leads to late embryonic and neonatal lethality owing to 
ventricular septal defects and chamber dilatation (61, 
62). Likewise, the targeted omission of the miR-17~92 
cluster causes similar cardiac abnormalities (63). 
Some patients with Down syndrome and DiGeorge 
syndrome have congenital heart diseases as well. The 
overexpression of 5 miRNAs-namely miR-99a, let-
7c, miR-125b-2, miR-155, and miR-802-which are 
located on human chromosome 21, has been found in 
the cardiac tissues of patients with Down syndrome 
(36, 64, 65). Interestingly, the critical region on 
chromosome 22 (22q11.2), which encodes a component 
of the RISC complex and is crucial for miR biogenesis 
is deleted in DiGeorge syndrome, which is due to the 
haploinsufficiency of this disease. The dysregulation of 
miR expression may, therefore, play a role in the gene 
dosage sensitivity of this disease via impacting many 
miR targets (66, 67).
miRNAs in rheumatic heart disease
Rheumatic heart disease is an autoimmune response 
to acute rheumatic fever (68), which occurs as a result 
of a bacterial infection with streptococcal bacteria (69). 
The heart could be inflamed with recurrent and repeated 
episodes of acute rheumatic fever, triggering the chronic 
inflammation of the myocardium and endocardium, 
hemodynamic alteration, valvular dysfunction (70) , and 
finally heart failure, stroke, arrhythmias, endocarditis, 
or other related complications. Patients with rheumatic 
heart disease are commonly diagnosed too late with 
severe and irreversible valvular dysfunction, which 
may necessitate cardiac surgery. Therefore, a specific 
diagnostic method is required to start effective therapies 
for these patients at the early stage of the disease. 
Finding novel biomarkers can confer early detection and 
characterization of the pathophysiology of rheumatic 
heart disease with a view to avoiding cardiac surgery 
(71). 
Recently, as is the case with other cardiovascular 
diseases, research has highlighted the role of miRNAs 
in the diagnosis and treatment of rheumatic heart 
disease. In this regard, the results obtained through 
miRNA array have shown that miR-1183 and miR-
1299 are significantly up-regulated in these patients. 
Moreover, increased levels of miR-1183 and miR-1299 
expression have been found either in the plasma or in 
the tissues of patients with rheumatic heart disease, 
which confirms that these miRNAs can be considered 
potential biomarkers in this autoimmune response 
(72). It should be noted that the expression of miR-
1183 in patients suffering from rheumatic heart disease 
with a high pulmonary artery systolic pressure is 
different from that in patients with a low pressure. This 
difference could suggest that the overexpression of miR-
1183 is due to the remodeling of the pulmonary artery 
secondary to rheumatic heart disease. Such findings 
show that the role of miR-1183 in secondary disease 
is more prominent than that in primary complications. 
An investigation discovered that miR-1299 could 
regulate rheumatic heart disease directly (72). A 
novel investigation on miRNAs participated in atrial 
fibrillation due to rheumatic heart disease revealed 
the important role of miR-29b-1-5p and miR-29b-2-
5p, which act through the down-regulation of various 
circular RNAs such as circRNA_10998, circRNA_11017, 
circRNA_11040, and circRNA_11044 (73).
The expression of some miRNAs such as miR-4423-
3p, miR-218-1-3p, and miR-101 is significantly down-
regulated in patients with rheumatic heart disease (74), 
and in children with rheumatic carditis miR-16-5p, miR-
223-3p, and miR-92a-3p are suppressed (75). miR-101 
has a role in regulating the immune system by altering the 
toll-like receptor 2 (TLR2) expression and through this 
pathway can suppress the immune system in patients 
with rheumatic heart disease (74).  However, Zhu et 
al. showed that miR-101 functioned as an activator of 
immune response through reducing mitogen-activated 
protein kinase phosphatase 1 (MKP1), which modulates 
the TLR4 pathway negatively (76). This controversy may 
be related to the complexity of miRNA action and the 
specificity of the tissue.
Recently published study using next generation 
sequencing of the miRNA profile of patients with 
rheumatic heart disease showed that hsa-miR-205-3p 
and hsa-miR-3909, are involved in the inflammatory 
pathway by targeting the IL-1β-IL-1 receptors. These 
target genes have a crucial role in progression of 
rheumatic heart disease (77).
Further mechanistic studies should, therefore, be 
performed to shed light on the modulatory role of 
miRNAs in the pathogenesis of rheumatic heart disease 
and to find new diagnostic and treatment approaches 
(78). 
Some miRNAs that have already been investigated 
in the other cardiovascular diseases like miR574-5p, 
miR-208a, miR-208b, and miR-206 (79)  could have 
regulatory roles in rheumatic heart disease, but it is 
necessary to perform more investigations to confirm 
their functions.
miRNA-based therapeutic approaches in 
cardiovascular disorders
In recent years increasing research in the 
cardiovascular field has revealed the possible role of 
miRNAs as biomarker and therapeutic targets for the 
diagnosis and treatment of cardiovascular disorders. 
In this context, reinstating the miRNA expression 
levels is the main approach in miRNA-based therapy. 
Generally 2 different methods have been recognized 
to modify miRNA expression levels in diseases 
(Figure 2). Since miRNA activity has either harmful or 
beneficial effects, the overexpressed miRNAs could be 
suppressed by antisense oligonucleotides and down-
regulated ones could be overexpressed and activated 
by oligonucleotides mimicking its function for the 
treatment of diseases. One of the approaches to the up-
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regulation of miRNAs for therapeutic purposes is the 
use of adeno-associated viruses (AAVs). The injection 
of beneficial miRNAs with AAVs into the host leads to 
a long-lasting expression of the miRNAs in vivo (80). 
In this method, it is necessary to find novel variants 
of AAVs to target specific cells or tissues. For example, 
9, 8, and 6 subtypes of AAVs have cardiotropic effects 
when applied systemically (81). Another approach is 
the use of modified synthetic oligonucleotides, which 
are able to mimic the functions of endogenous miRNAs. 
The challenging aspects of this method are the design 
and delivery of double-stranded oligonucleotides. In the 
inhibitory approach, anti-miRNAs or antagomiRs are 
applied for the down-regulation of the harmful miRNA. 
The antagomiRs are single-stranded oligomers that are 
designed for the targeted miRNA (82, 83). 
From 1983 to 2017, different major biopharmaceutical 
companies were involved in the development of the 
therapeutic miRNA molecules. Among them Santaris 
Pharma from Denmark developed an inhibitor, a short 
locked nucleic acid (LNA), of miR-122 named miravirsen, 
which is currently moving toward the market. This 
miRNA therapeutic, which is the world’s first miRNA-
based drug is presently in phase II clinical trials for the 
treatment of hepatitis C virus (HCV) infection (84, 85).
In addition, several biopharmaceutical companies are 
developing other miRNA therapeutics for treatment of 
different diseases, as well as cardiovascular disorders. 
But all of them are in the preclinical stage and aiming to 
enter clinical trials (86).
Miragen therapeutics company is working on at 
least six miRNAs therapeutics related to cardiovascular 
disorders. In line with this, MGN- 1374, which targets 
miR-15 and miR-195, is in the preclinical stage for 
the treatment of post-myocardial infarction. All MGN-
2677, MGN-4220, MGN-5804, MGN-6114, and MGN-
9103 miRNA-based drugs are in the pipeline of clinical 
trials. Abovementioned therapeutic drugs target miR-
143/145, miR-29, miR-378, miR-92, and miR-208, 
respectively (40, 87-89). Overall, miRNA-based therapy 
for cardiovascular diseases could be challenging because 
the substances that target miRNAs have unique features 
in terms of nonselective uptake and susceptibility to 
degradation. Consequently, in this therapeutic approach, 
it is necessary to design highly stable reagents so as to 
prevent their degradation during their passage from 
cellular membranes. 
Conclusion
In the modern era, discovery of the role of miRNAs 
in the development of the cardiovascular system and 
pathogenesis of related diseases has reformed our 
perspective on appropriate treatment modalities. 
Nevertheless, despite the remarkable array of research 
on miRNAs in physiological and pathological state of 
the cardiovascular system, we have simply just begun 
to clarify the complexity of the heart and vascular 
system. The ever-growing body of research on the role 
that miRNAs play in diverse biological processes of the 
cardiovascular system will surely enable us to further 
scrutinize their functions and targets and to determine 
the miRNA-mRNA and miRNA-ncRNA complex 
interactions. 
The discovery of microRNA-based drugs is considered 
one of the most breathtaking therapeutic advances in 
biopharmaceuticals that will enter into commercial 
space as upcoming medicines. The optimization of 
some limitations like safety, efficacy, target selection, 
and delivery technologies, as well as clinical trial design 
and commercial considerations, will be in need of 
producing successful drugs. Furthermore, uncovering 
novel signaling mechanisms in the miRNA-based 
regulation will undoubtedly boost our knowledge about 




Figure 2. Targeted therapy with antagomir and agomir
Antagomirs are engineered single-stranded oligonucleotides that inhibit molecules binding to a desired region on the mRNA molecule and 
specifically are applied to silence endogenous microRNA. Targeting miRNAs by antagomirs in the cells with overexpression of miRNA inhibits 
and suppresses the function of miRNA and increase expression of target proteins (left side). Agomirs (mimics) are chemically modified double-
stranded miRNA that can regulate the function of target gene through the mimicking endogenous miRNA. In the cells with low endogenous level 
of miRNA, Agomirs lead to derepression of the target proteins (right side). Agomirs and antagomirs have a high affinity for cell membrane and can 
be richened in target cells and induce specific and stable interfering effects
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introducing novel candidate miRNAs for therapeutic 
approaches.
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